187 filings
Page 2 of 10
8-K
vnhihdjcmu8saybj 4sm
17 Jun 24
Keros Therapeutics Announces Leadership Updates
4:02pm
8-K
s567cos8xad7v
17 Jun 24
Other Events
6:07am
8-K
di1w4rjiz
4 Jun 24
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
8:01am
8-K
zblabaogj52g7am8z
3 Jun 24
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
8:01am
8-K
x6oq99seb
30 May 24
Submission of Matters to a Vote of Security Holders
4:01pm
8-K
sh053 sw8kwm
28 May 24
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
4:02pm
8-K
eeernzz 0s3af85
8 May 24
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
8:01am
S-3ASR
6y7sicm
3 May 24
Automatic shelf registration
8:00am
ARS
duforzl3k02bhc
17 Apr 24
Annual report to shareholders
4:08pm
DEFA14A
5is4omnhzy
17 Apr 24
Additional proxy soliciting materials
4:05pm
8-K
9x8tw
14 Mar 24
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
8:01am
8-K
ubx7yx0wklbh t4p3q
6 Mar 24
March 2024 Corporate Presentation
8:01am
8-K
bu2ddn0
5 Mar 24
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
8:02am
8-K
ga8s8
5 Mar 24
Departure of Directors or Certain Officers
8:01am
S-8
kqztma
28 Feb 24
Registration of securities for employees
5:41pm
8-K
pl5dbv
28 Feb 24
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
4:02pm
8-K
u56x m1zaxqn
9 Jan 24
Keros Therapeutics Announces Closing of Upsized Public Offering of Common Stock
8:01am
8-K
gzjvwgb8a
4 Jan 24
Other Events
4:04pm